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Abstract
Background and Aims: Risankizumab, an interleukin-23 antibody, demonstrated efficacy and 
acceptable safety in a phase 2 study of patients with moderate-to-severe refractory Crohn’s disease. 
This open-label extension investigated the long-term safety, pharmacokinetics, immunogenicity 
and efficacy of risankizumab in responders to risankizumab in the parent phase 2 study.
Methods: Enrolled patients had achieved clinical response [decrease in Crohn’s Disease Activity 
Index from baseline ≥100] without clinical remission [Crohn’s Disease Activity Index <150] at Week 
26, or clinical response and/or remission at Week 52 in the parent phase 2 study and received open-
label subcutaneous risankizumab 180 mg every 8 weeks.
Results: Sixty-five patients were enrolled, including four who had lost response in the parent study 
and were first reinduced with risankizumab 600 mg every 4 weeks [three infusions]. Patients received 
risankizumab for a median of 33 months [total: 167.0 patient-years]. The rate of serious adverse events 
was 24.6 events/100 patient-years; the majority were gastrointestinal in nature. Rates of serious infections, 
opportunistic infections and fungal infections were 4.2, 1.8, and 6.6 events/100 patient-years, respectively. 
No deaths, malignancies, adjudicated major adverse cardiovascular events, latent/active tuberculosis or 
herpes zoster were reported. Treatment-emergent anti-drug antibodies developed in eight patients [12.3%]; 
none were neutralizing. Efficacy outcomes were maintained during the study, including the proportions of 
patients [observed analysis] with clinical remission [>71%] and endoscopic remission [>42%].
Conclusions: Long-term maintenance treatment with subcutaneous risankizumab 180 mg every 
8 weeks was well tolerated by patients with Crohn’s disease, with no new safety signals.
Key Words: Crohn’s disease; long-term safety; open-label extension
Clinical trial registration number: NCT02513459
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1. Introduction
Crohn’s disease [CD] is an inflammatory bowel disease character-
ized by chronic relapsing inflammation in the gastrointestinal tract. 
Signs and symptoms of CD include abdominal pain, chronic diar-
rhoea, fever, weight loss and fistula drainage, which represent a con-
siderable systemic burden for patients.1,2 The reported worldwide 
incidence [0.0–29.3 per 100 000 person-years] and prevalence [0.9–
322.0 per 100 000 persons] of CD vary greatly across geographical 
regions, with a prevalence of >0.3% in North America, Oceania and 
many countries in Europe.3 While the incidence in newly industrial-
ized countries in Africa, Asia and South America is typically lower 
than in westernized countries, the incidence of CD is also rising in 
these countries.3,4
Current treatments for CD include corticosteroids, thiopurines, 
methotrexate, tumour necrosis factor [TNF] antagonists, the integrin 
antagonist vedolizumab and the interleukin [IL]-12/23 inhibitor 
ustekinumab.2,5 The European Crohn’s and Colitis Organisation 
and the American College of Gastroenterology recommend using 
corticosteroids, TNF antagonists [adalimumab, infliximab and 
certolizumab pegol], vedolizumab and ustekinumab to induce re-
mission in patients with moderate-to-severe CD; and recommend 
thiopurines, methotrexate, TNF antagonists, vedolizumab and 
ustekinumab for the maintenance of remission.2,5 However, approxi-
mately one-third of patients do not respond to TNF antagonists or 
lose their response to TNF antagonists over time.1
Risankizumab is a fully human immunoglobulin G monoclonal 
antibody that binds with high affinity to the p19 subunit of IL-23, 
which has been approved for the treatment of moderate-to-severe 
plaque psoriasis.6,7 Results from the phase 2 M15-993 study showed 
that risankizumab was effective and well tolerated through 52 weeks in 
patients with moderate-to-severe CD, the majority of whom had failed 
prior therapy with one or more TNF antagonists.8,9 In the blinded in-
duction period, a greater proportion of patients achieved clinical and 
endoscopic remission after 12 weeks of treatment with risankizumab 
600 mg intravenous [IV] every 4 weeks [Q4W] compared with pla-
cebo. Risankizumab 600 mg IV treatment in the open-label reinduction 
period increased remission rates at Week 26, and remission was ef-
fectively maintained with risankizumab 180  mg subcutaneous [SC] 
through Week 52. Over 52 weeks, treatment-emergent anti-drug anti-
bodies [ADAs] were observed in 8% of patients who received at least 
one dose of risankizumab; none were neutralizing.9 Pooled phase 1 
and 2 population pharmacokinetics data from patients with psor-
iasis or CD demonstrated that body weight had a modest effect on 
risankizumab exposure, while baseline serum albumin levels were stat-
istically correlated with risankizumab clearance but had no clinically 
meaningful impact on serum concentrations of risankizumab.10
Patients who responded to risankizumab in the phase 2 study 
were eligible to enrol in the open-label extension [OLE] M15-989 
study reported here. The objective of this OLE was to investigate the 
long-term safety, pharmacokinetics, immunogenicity, efficacy and 
health-related quality of life [HRQoL] of risankizumab, in patients 
with moderate-to-severe active CD who achieved a clinical response 
or remission on previous treatment with risankizumab.
2. Methods
2.1. Study design and patients
Patients who successfully completed the phase 2 M15-993 study 
[NCT02031276] were eligible to enrol in this single-group OLE 
[M15-989; NCT02513459; US Clinical Trials Registry]. Patients 
were included from 38 referral sites across Europe, Asia and North 
America. All patients received maintenance therapy with open-label 
risankizumab 180  mg SC every 8  weeks [Q8W] up to 196  weeks 
[Figure 1]. Successful completion of M15-993 was defined as achieve-
ment of clinical response [decrease in Crohn’s Disease Activity Index 
[CDAI] from baseline with ≥100 points] without clinical remission 
[CDAI <150] at Week 26 or achievement of clinical response and/
or remission at Week 52.9 Patients who had lost clinical remission 
at the end of the trial visit for the M15-993 study, or at screening for 
the M15-989 OLE, received open-label reinduction of risankizumab 
with three infusions of 600 mg IV Q4W, after which eligibility was re-
assessed. If clinical response or remission was achieved, patients were 
switched to maintenance treatment of risankizumab 180 mg SC Q8W 
from visit 5 for the remainder of the OLE. Patients who completed 
the M15-989 study could elect to enrol in the M16-000 sub-study 3, 
an ongoing phase 3 OLE [NCT03105102], in which they continue 
to receive open-label risankizumab 180 mg SC Q8W and are eligible 
to receive risankizumab rescue therapy. The M15-989 study was ter-
minated by the sponsor to provide the option for patients to roll over 
for continuous open-label treatment within the ongoing phase 3 OLE.
Inclusion and exclusion criteria in the parent M15-993 study 
have been previously described.8 In brief, patients were adults [aged 
18–75 years] with moderate-to-severe CD, defined as CDAI 220–450 
and Crohn’s Disease Endoscopic Index of Severity [CDEIS] ≥7 [or 
≥4 for patients with isolated ileitis] with mucosal ulcers in the ileum 
and/or colon. Patients could have been biologic-naïve or previously 
treated with one or more TNF antagonists or vedolizumab, while pa-
tients who had received ustekinumab were ineligible for enrolment.
During the OLE, patients were permitted to continue oral cor-
ticosteroids [prednisone equivalent dose of ≤20  mg/day], oral 
5-aminosalicylates and immunosuppressive agents [azathioprine, 
6-mercaptopurine or methotrexate] if they had been on a stable dose 
for ≥4 weeks prior to visit 2. Patients who entered the OLE on con-
comitant treatments were required to continue on the stable dose 
throughout the OLE. Initiation of systemic antihistamines and IV 
steroids was permitted in the case of infusion reactions during or 
after risankizumab infusion in accordance with the severity of the 
reaction and the local standard of care.
The M15-989 OLE was conducted in accordance with the 
International Conference on Harmonization guidelines, applic-
able regulations and the Declaration of Helsinki. Study-related 
documents were approved by institutional ethics committees and 
review boards. All patients provided written, informed consent. 
An independent data monitoring committee was utilized to en-
sure that the welfare of patients participating in this study was 
maintained.
2.2. Outcomes
The primary objective was to assess long-term safety in patients 
with CD receiving maintenance risankizumab 180  mg SC Q8W. 
Adverse events [AEs], vital signs and laboratory assessments were 
collected throughout the study and up to 20  weeks after the last 
dose of risankizumab for patients who prematurely discontinued the 
study. AEs were coded using the Medical Dictionary for Regulatory 
Activities version 21.1, and severity was graded based on the 
Rheumatology Common Toxicity Criteria version 4.0. Major car-
diac, cerebrovascular and thrombotic events were adjudicated by an 
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Treatment-emergent AEs [TEAEs] were defined as events occurring 
or worsening either on or after the first dose of risankizumab in the 
M15-989 study; within 20 weeks after the last dose of risankizumab 
for patients who prematurely terminated the study drug in the M15-
989 study; and before the first dose of risankizumab in the phase 3 
OLE. Duration of risankizumab exposure was defined as the date of 
last risankizumab dose minus the date of first risankizumab dose in 
the M15-989 OLE plus 8 weeks. AEs are presented as the number of 
patients [%] experiencing any event, the absolute number of events 
and events per 100 patient-years [E/100 PY].
Preceding phase 2 study: M15-993 (Baseline)
121 patients were randomized and treated:
107 patients completed Week 12 and continued study
39 patients randomized to placebo IV
6 patients achieved deep remission and entered washout
41 patients randomized to risankizumab 200 mg IV Q4W
41 patients randomized to risankizumab 600 mg IV Q4W
101 patients allocated to open-label risankizumab 600 mg IV Q4W
20 patients achieved clinical
response (but no remission) at
Week 26 and stopped treatment
62 patients achieved clinical remission at
Week 26 and received open-label
risankizumab 180 mg SC Q8W
50 patients achieved
clinical remission or




Phase 2 OLE study: M15-989 (Week 0)
61 patients rolled over to the phase 2
OLE and received open-label
risankizumab 180 mg SC Q8W
 49 patients achieved clinical remission
and/or response at Week 52
 12 patients achieved clinical response
(without clinical remission) at Week 26
4 patients who lost response in
M15-993 rolled over to the phase 2
OLE and were reinduced with
risankizumab 3 × 600 mg IV Q4W
3 patients had lost response after Week 26
1 patient had lost response after Week 52




(baseline to Week 12):
Blinded induction
(Week 14 to 26):
Extended induction or
washout






(Week 0 to 12):
Reinduction or
maintenance
(Week 12 to up to 196):
Maintenance
 4 patients who were rst reinduced achieved clinical response and/or remission by Week 12 and
switched open-lable risankizumab 180 mg SC Q8W
21 (32%) patients discontinueda
7 AEs
4 withdrew by patient
10 other reasonsb
2 loss of efcacy
2 patient decision
2 pregnancies







44 (68%) patients completed M15-989
Phase 3 OLE study : M16-000 sub-study 3
Phase 3 OLEc
(up to Week 220)
44 patients transitioned into the ongoing risankizumab CD phase 3 OLE (M16-000 sub-
study 3) from M15-989 and continued open-lable risankizumab 180 mg SC Q8W
Figure 1. Study design and patient disposition. aPrimary reasons for discontinuation. bOther reasons are as reported by the investigator [as free text] and have 
not been grouped to avoid inaccuracy in reporting. cPatients rolled over to the ongoing phase 3 OLE [M16-000 sub-study 3] between Weeks 128 and 184 of M15-
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Secondary objectives included the assessment of pharmacokin-
etics, immunogenicity, efficacy and HRQoL. Plasma samples were 
collected at scheduled visits, and were analysed at a later date using 
an enzyme-linked immunosorbent assay to measure risankizumab 
plasma concentration and an electrochemiluminescence assay with 
a three-tiered approach for the detection of ADAs.8 Due to sparse 
sampling, only trough plasma concentrations at the time relative to 
the first SC dose were summarized. Key efficacy outcomes included 
clinical remission [CDAI <150] and endoscopic remission [CDEIS 
≤4, or ≤2 for patients with isolated ileitis]; HRQoL outcomes in-
cluded Inflammatory Bowel Disease Questionnaire [IBDQ] response 
[increase from baseline in IBDQ total score ≥16] and remission 
[IBDQ total score ≥170]; and biomarker outcomes included median 
change from baseline in serum albumin, high-sensitivity C-reactive 
protein [hs-CRP] and faecal calprotectin. CDAI scores and hs-CRP 
levels were assessed at every visit; IBDQ scores and serum albumin 
concentrations were assessed every 24 weeks; faecal calprotectin was 
assessed at baseline, Week 24 and every 32 weeks thereafter; and 
ileocolonoscopies were performed yearly. Central scoring of endos-
copy results was performed by independent, blinded reviewers for all 
endoscopic assessments.
2.3. Statistical analysis
Safety data were reported for patients who received at least one dose 
of risankizumab [safety analysis set]. The pharmacokinetics and im-
munogenicity analysis set included all patients who had pharma-
cokinetics and ADA data. Efficacy and HRQoL data were reported 
for the intent-to-treat population with non-responder imputation 
[NRI] of missing data up to Week 128. This was because from that 
time point onwards patients could roll over to the phase 3 OLE, 
resulting in a decrease in the number of patients continuing in the 
current phase 2 OLE study towards its completion and prior to the 
roll over into the phase 3 OLE for further risankizumab treatment 
and follow-up. Therefore, only observed cases were reported beyond 
Week 128. Note that the final time point reported may vary for dif-
ferent efficacy outcomes according to the frequency of assessments 
described in the previous section, and that patients completed M15-
989 at different time points to roll over into the phase 3 OLE. No 
sample size calculation or statistical comparisons were conducted; 
all analyses were summarized descriptively. Week 0 denotes the first 
dose of study drug in the M15-989 OLE. However, for baseline char-
acteristics and changes from baseline, baseline was defined as being 
prior to the first dose of study drug in the parent M15-993 study.8
3. Results
3.1. Patient disposition
Of the 121 patients randomized in the M15-993 study,9 65 rolled 
over to this OLE [all risankizumab group] from September 2015 
onwards. This included patients who achieved clinical response 
[without clinical remission] at Week 26 [n  =  12], patients who 
achieved clinical remission and/or response at Week 52 [n = 49] and 
four patients who had lost response at the end of the M15-993 study 
and were reinduced with risankizumab 600 mg IV Q4W at the be-
ginning of the OLE [Figure 1]. Forty-four patients [68%] completed 
the M15-989 study and transitioned into the phase 3 OLE, while 21 
[32%] patients prematurely discontinued the current study. Seven 
patients discontinued the study due to AEs and seven patients with-
drew consent; all reasons for discontinuation are detailed in Figure 
1. The M15-989 study concluded in June 2019; it was terminated 
by the sponsor to provide the option for patients to roll over to 
continuous open-label treatment within the ongoing phase 3 OLE.
Baseline characteristics and disease activity [i.e. at entry into the 
M15-993 study] of the OLE population are presented in Table 1. 
Median CD duration was 10.0 years [range: 2.0–38.0], and 92.3% 
of patients had been previously treated with at least one TNF 
antagonist.
3.2. Safety
In the all risankizumab group [n = 65], the treatment duration of 
risankizumab ranged from 114 to 1317  days, with a median of 
1014 days [33 months] and a total of 167.0 PY. Forty patients [62%] 
received risankizumab for >924 days. All patients who required IV 
reinduction [n  =  4] received the full reinduction with three infu-
sions of 600 mg IV risankizumab Q4W [median duration: 84 days] 
and achieved clinical response by Week 8; they then continued 
risankizumab 180 mg SC Q8W from Week 12 onwards.
Most patients experienced at least one TEAE [Table 2]. The most 
common TEAEs were nasopharyngitis, gastroenteritis and fatigue 
[Supplementary Table 1]. Serious AEs [SAEs] were reported in 23 
patients [35.4%; 24.6 E/100 PY]. SAEs observed in more than one 
patient were worsening CD, intestinal stenosis, viral gastroenteritis, 
peritonitis and post-procedural complications [n = 2 each]. Six pa-
tients [9.2%; 4.2 E/100 PY] discontinued the study drug due to the 
following TEAEs: worsening CD [n = 5], including one patient with 
colon injury [intraluminal laceration of the colon with no perfor-
ation during an endoscopy], and ileal stenosis [n  = 1]. No deaths 
were reported.
Infections were reported in 48 patients [73.8%; 112.0 E/100 PY]. 
The most common infections were nasopharyngitis, lower respira-
tory tract infection, oral herpes and urinary tract infection. Serious 
infections were reported in six patients [9.2%; 4.2 E/100 PY]; these 
included pelvic peritonitis secondary to anal dilatation and viral 
gastroenteritis [reported in the same patient], peritonitis following 
ileocaecal resection surgery, Campylobacter infection, subcutaneous 
abscess, viral gastroenteritis and perianal abscess. None of the ser-
ious infections led to discontinuation of risankizumab. Of the six 
patients with serious infections, two were receiving concomitant 
immunomodulators [n  =  1] or corticosteroids [n  =  1] throughout 
the OLE. Opportunistic infections were reported in three patients 
[4.6%; 1.8 E/100 PY] and included fungal oesophagitis and oral 
fungal infection; all were resolved during the study period. Fungal 
infections were reported in seven patients [10.8%; 6.6 E/100 PY]. 
Oral fungal infection and vulvovaginal mycotic infection were most 
frequently reported [n  =  2 each]. The remaining fungal infections 
were single events of Blastocystis infection, fungal infection of the 
hands and feet, fungal oesophagitis, fungal skin infection, tinea 
capitis and vulvovaginal candidiasis. None of these were serious [all 
grade 1 or 2], and none led to treatment discontinuation. No events 
of tuberculosis or herpes zoster infections were reported.
Hypersensitivity reactions were reported in 16 patients [24.6%; 
10.2 E/100 PY]. The most frequently reported hypersensitivity 
reactions were rash [n  = 5] and eczema [n  = 3]. Five events were 
considered to be related to the study drug according to the investi-
gator, and no events led to discontinuation of risankizumab treat-
ment. All hypersensitivity reactions were assessed as grade 1 or 2, 
except for one SAE, which was an anaphylactic reaction due to iron 
carboxymaltose [Ferinject] infusion.
Hepatic events were reported in six patients [9.2%; 10.2 E/100 
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Table 1. Patient characteristics at baselinea and Week 0b [intent-to-treat analysis set]
Patient characteristics at baselinea All risankizumab [N = 65]
Age, years, median [range] 34.0 [19–67]
Female, n [%] 36 [55.4]
Race, white, n [%] 55 [84.6]
Weight, kg, median [range] 66.0 [41.0–123.9]
Disease duration, years, median [range] 10.0 [2.0–38.0]
CD location, n [%]
 Ileocolonic 37 [56.9]
 Colonic only 20 [30.8]
 Ileum only 8 [12.3]
Prior TNF antagonist use, n [%] 60 [92.3]
 Prior use of one TNF antagonist 20 [30.8]
 Prior use of two TNF antagonists 32 [49.2]
 Prior use of three TNF antagonists 8 [12.3]
Concomitant treatment,c n [%]
 Corticosteroid only 13 [20.0]
 IMM only 21 [32.3]
 Corticosteroid and IMM 9 [13.8]
Disease activity Baseline,a median [range] Baseline,a mean [SD] Mean [SD] change from baseline at Week 0b
CDAI 298.0 [109.0–477.6] 304.8 [78.0] −198.5 [101.8]
CDEIS 11.9 [5.2–25.0] 13.3 [5.6] −8.1 [6.0]
IBDQ 114.0 [52.0–182.0] 114.3 [34.4] 62.5 [38.8]
hs-CRP, mg/L 10.2 [0.2–109.0] 20.3 [23.2] −14.6 [22.8]
Faecal calprotectin, mg/kg 1364.0 [40.0–25 252.0] 2436.5 [3707.0] −1983.9 [3402.1]
CD, Crohn’s disease; CDAI, Crohn’s Disease Activity Index; CDEIS, Crohn’s Disease Endoscopic Index of Severity; hs-CRP, high-sensitivity C-reactive protein; 
IBDQ, Inflammatory Bowel Disease Questionnaire; IMM, immunomodulator; OLE, open-label extension; SD, standard deviation; TNF, tumour necrosis factor.
aBaseline is defined as prior to first dose of study drug in the parent M15-993 study. 
bWeek 0 is defined as first dose of study drug in the M15-989 OLE. 
cPatients were permitted to continue oral corticosteroids [prednisone equivalent dose of ≤20 mg/day] and immunomodulators [azathioprine, 6-mercaptopurine 
or methotrexate] if they had been on a stable dose for at least 4 weeks prior to visit 2. Patients who entered the OLE on concomitant treatments were required 
to continue on a stable dose of this treatment throughout the M15-989 OLE. 
Table 2. Overview of TEAEs [safety analysis set]
All risankizumab [N = 65; PY = 167.0]
Number of patients [%] E/100 PY
Any AE 60 [92.3] 408.4
AE possibly related to study druga 26 [40.0] 49.7
Serious AE 23 [35.4] 24.6
Severe AEb 14 [21.5] 15.0
AE leading to discontinuation of study drug 6 [9.2] 4.2
All deaths 0 0
Infection 48 [73.8] 112.0
 Serious infection 6 [9.2] 4.2
 Opportunistic infection 3 [4.6]c 1.8
 Fungal infection 7 [10.8]c 6.6
 Tuberculosis 0 0
 Herpes zoster 0 0
Malignancy excluding NMSC 0 0
Hypersensitivity 16 [24.6] 10.2
Anaphylactic reaction 1d [1.5] 0.6
Hepatic event 6 [9.2] 10.2
Adjudicated MACE 0 0
AE, adverse event; E/100 PY, events per 100 patient-years; MACE, major adverse cardiovascular event; NCI, National Cancer Institute; NMSC, non-melanoma 
skin cancer; PY, patient-years; TEAE, treatment-emergent adverse event.
aAs assessed by the investigator.
bAEs with NCI toxicity ≥grade 3 or unknown severity.
cOf all fungal infection cases, fungal oesophagitis [n = 2] and oral fungal infection [n = 1] were also coded as opportunistic infections.
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of hepatic steatosis was observed in a patient with a body mass 
index >30 kg/m2. All hepatic events were assessed as grade 1, none 
were serious and none led to discontinuation of risankizumab. 
Potentially clinically important increases in liver enzymes were rare 
[Supplementary Table 2], and increases in alanine aminotransferase 
and aspartate aminotransferase returned to normal levels during the 
OLE. No patients met the criteria for Hy’s Law.
No malignancies or adjudicated major adverse cardiovascular 
events were reported during this OLE study.
In general, changes in laboratory values were not considered 
clinically meaningful [Supplementary Table 2]. There were few 
individual cases of ≥grade 3 laboratory values and most of them 
were transient. Three patients had ≥grade 3 decreases in lympho-
cytes, of whom two had ≥grade 3 decreases only once during 
the study, and all decreases resolved without discontinuation. Six 
patients had ≥grade 3 increases in creatine kinase, five of whom 
experienced increases only once during the study, and three of 
whom experienced increases during the follow-up period. All in-
creases resolved without discontinuation. Most of these events 
were assessed by the investigator as temporary and not clinically 
meaningful. Five patients experienced ≥grade 3 increases in tri-
glycerides, one of whom had increased triglycerides prior to this 
study. No persistent trend was observed. All increases in trigly-
cerides resolved, and no patients discontinued risankizumab due 
to increases in triglycerides.
Three pregnancies were reported during this OLE: two preg-
nancies occurred during maternal treatment with risankizumab 
180 mg SC Q8W, and the third was the pregnancy of a patient’s 
partner. Maternal use of risankizumab was discontinued after 
pregnancy was confirmed. One of the patients with maternal use 
of risankizumab pre-conception and during the first trimester 
[having received risankizumab treatment for 575 days in total] 
surgically terminated her pregnancy because of fetal defects [fetal 
cystic hygroma and hydrops fetalis] 78 days after risankizumab 
was discontinued; this was considered by the investigator as 
having a reasonable possibility of being related to risankizumab. 
This patient subsequently had a second pregnancy outside the 
OLE reporting period [after discontinuation of risankizumab for 
>20 weeks and therefore not included as one of the three preg-
nancies that occurred during the OLE], which resulted in a mis-
carriage. The other two pregnancies concluded with live births 
without any reported complications or abnormalities.
3.3. Pharmacokinetics and immunogenicity
Steady-state plasma exposures of risankizumab were reached by Week 
24 and were maintained throughout the study, with geometric mean 
trough concentrations ranging from 3.2 to 4.0 μg/mL [Figure 2].
At Week 0 [prior to first risankizumab dose in M15-989], pre-
existing ADAs were detected in 2/65 patients [3%] who received at 
least one dose of risankizumab in the study, possibly due to prior 
exposure to risankizumab in the parent phase 2 study M15-993. 
Treatment-emergent ADAs developed in 8/65 patients [12%] during 
this OLE, none of whom developed neutralizing antibodies. Four 
patients with treatment-emergent ADAs discontinued from the study 
for the following reasons: AE, pregnancy, withdrawal of consent and 
lack of efficacy, respectively. ADA titres ranged from 1 to 64 with no 
apparent impact on risankizumab plasma exposure in all but one 
patient. Further pharmacokinetic and immunogenicity data will be 
collected and their correlations with safety and efficacy outcomes 
will be analysed in phase 3 studies.
3.4. Efficacy, HRQoL and biomarkers
The proportions of patients in clinical remission and endoscopic re-
mission were maintained with long-term risankizumab treatment 
throughout the duration of the study. Central reviewer scoring was 
used for all endoscopic efficacy assessments. Clinical remission was 
achieved in >71% of patients in the observed analysis and >64% 
of patients in the NRI analysis at any given visit through Week 112 
of OLE therapy [Figure 3A]. Endoscopic remission was achieved in 
>42% of patients in the observed analysis and >41% of patients in 
the NRI analysis at any given visit through Week 104 [Figure 3B].
A high proportion of patients reported HRQoL improvements 
from baseline [prior to the first dose of risankizumab in the M15-
993 study], assessed by IBDQ response [>88% of patients in the 
observed analysis and >70% of patients in the NRI analysis; Figure 
3C] and IBDQ remission [>58% of patients in the observed analysis 
and >52% of patients in the NRI analysis; Figure 3D] at any given 
visit through Week 120. These improvements were observed across 
all four domains of the IBDQ [bowel symptoms, systemic symptoms, 
social function and emotional function].
Median reductions from baseline [prior to the first dose 
of risankizumab in the M15-993 study] in hs-CRP and faecal 
calprotectin observed at Week 0 of this OLE were generally main-
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Figure 2. Risankizumab trough plasma concentration over time in all patients. Analysis set included all patients with available pharmacokinetics and ADA data. 
Patients rolled over to the ongoing phase 3 OLE [M16-000 sub-study 3] between Weeks 128 and 184, and as a result had different last visit time points. ADA, 
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Figure 1A and B]. Increased serum albumin levels at Week 0 were also 
generally maintained through Week 152 [Supplementary Figure 1C].
4. Discussion
In this OLE, risankizumab 180 mg SC Q8W maintenance treatment 
was well tolerated by patients with CD with over 3 years and 167 PY 
of treatment, and no new safety signals were observed. As secondary 
outcomes, the pharmacokinetics of risankizumab were consistent 
with previous observations,9,10 and efficacy was maintained during 
the study. Patients included in this study had treatment-refractory 
CD at M15-993 baseline and completed both the M15-993 and 
M15-989 studies before rolling over to the phase 3 OLE, suggesting 
that the safety and efficacy of risankizumab were compelling enough 
to warrant continued risankizumab.
The majority of SAEs were gastrointestinal in nature and may 
reflect underlying CD. Rates of serious infections, opportunistic in-
fections and fungal infections in the OLE [4.2, 1.8, and 6.6 E/100 
PY, respectively] were similar to those reported in the parent phase 
2 M15-993 study [4.6, 2.7 and 7.3 E/100 PY, respectively].9 Serious 
infections were predominantly driven by gastrointestinal events, and 
no cases of tuberculosis [including latent tuberculosis] or herpes 
zoster were reported. Hypersensitivity reactions were observed in 
about 25% of patients and occurred at a lower rate than that ob-
served in the M15-993 study. There was one serious anaphylactic 
reaction to IV iron carboxymaltose administration that did not lead 
to drug discontinuation. No deaths, malignancies or adjudicated car-
diovascular events were reported.
Laboratory values ≥grade 3 were infrequent and usually tran-
sient. The safety profile of risankizumab 180 mg in patients with 
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Figure 3. Proportions of patients achieving clinical remission [A], CDEIS remission [B], IBDQ response [C] and IBDQ remission [D] over time [intent-to-treat 
analysis set]. From Week 128 onwards, patients could roll over to the ongoing phase 3 OLE [M16-000 sub-study 3]. This resulted in a decrease in the number 
of patients continuing towards completion in the current phase 2 OLE study and prior to rollover into the phase 3 OLE for further risankizumab treatment and 
follow-up. Therefore, NRI for missing data was not presented after Week 128. Only observed cases were presented beyond Week 128. n denotes the number 
of responders and N denotes the number of patients at risk. CDAI, Crohn’s Disease Activity Index; CDEIS, Crohn’s Disease Endoscopic Index of Severity; IBDQ, 
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CD was generally consistent with previous reports in psoriasis and 
psoriatic arthritis, despite the difference in risankizumab doses 
evaluated across indications [150  mg every 12  weeks for psor-
iasis and 150 mg every 4 or 12 weeks for psoriatic arthritis].11–13 
The types of TEAEs reported with risankizumab in patients with 
CD were similar to those reported by studies of ustekinumab, an 
IL-12/23 inhibitor.14–16
Of the three pregnancies reported during the OLE, two resulted 
in healthy births, while the third was surgically terminated due to 
fetal abnormalities. It is important to note that this OLE was not 
designed to evaluate the effects of risankizumab on pregnancies, as 
women of childbearing potential had agreed to use and remain on 
contraception from the date of screening until 20 weeks after the last 
dose of risankizumab treatment according to the protocol.
Steady-state plasma exposure was achieved by Week 24 fol-
lowing administration of risankizumab 180 mg SC Q8W. The devel-
opment of largely low-titre, non-neutralizing ADAs in eight patients 
was not expected to affect target binding sites on risankizumab 
and did not appear to have a clear impact on risankizumab plasma 
exposures. These results are consistent with previous studies of 
psoriasis, in which only high-titre ADAs [>128] for risankizumab 
had a meaningful impact on pharmacokinetics.17,18 Therefore, no 
marked impact on risankizumab exposure, and thus efficacy and 
safety, was expected given that the majority of the ADAs in this study 
were of low titre. However, these results should be interpreted with 
caution due to the small sample size of the study. Although four 
of the eight patients who developed treatment-emergent ADAs dis-
continued from the study, based on review of the time-course data 
for ADA titres, risankizumab exposure and reasons for discontinu-
ation there was no apparent correlation between immunogenicity 
and discontinuation.
The main limitation of this OLE was the relatively small sample 
size [n = 65]. Another limitation was that this study was not powered 
for statistical comparisons. The open-label study design and lack of 
comparator or control treatment arms meant that the study was 
more likely to be subject to bias than a randomized controlled trial. 
In addition, interpretation of safety outcomes is more challenging 
without a control group. However, objective evaluations including 
endoscopy were performed prospectively. As all patients were re-

































IBDQ response (increase from baseline in IBDQ total score > 16)
0 4824 72 96 120 144







64 65 65 65 65 52 65 61 65 65
59 58 58
60
57 57 46 46 46 46 46 46 37
4048
Time (weeks)











0 4824 72 96 120 144
Time (weeks)
40
64 65 65 65 65 52 65 51 65 65
40 38 38
60










/ecco-jcc/advance-article/doi/10.1093/ecco-jcc/jjab093/6291316 by guest on 22 July 2021
Risankizumab in Crohn’s Disease: Phase 2 OLE 9
OLE, the achievement of steroid-free response or remission could not 
be assessed. While the small sample size of this study may limit the 
generalizability of the findings, safety and efficacy data will be con-
firmed by ongoing phase 3 studies with larger patient populations.
In this OLE, maintenance treatment with risankizumab 180 mg 
SC Q8W for up to 184 weeks was well tolerated by patients with 
moderate-to-severe refractory CD, and no new safety signals were 
observed. Results from ongoing phase 3 studies, including the phase 
3 OLE, will further inform the efficacy and safety of risankizumab 
in patients with CD.
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